Holt P G
Institute for Child Health Research, West Perth, Australia.
Immunol Today. 1994 Oct;15(10):484-9. doi: 10.1016/0167-5699(94)90194-5.
Current research in the field of atopy is directed almost exclusively towards treatment of established allergic disease. In particular, treatment has concentrated on controlling the release and actions of various mediators, such as cytokines, from the allergy effector cells at the end of the immuno-inflammatory cascade. Here, Patrick Holt argues that a potentially more-effective and achievable goal may be the prevention of initial T helper 2 (Th2)-cell sensitization to environmental allergens during infancy. This might be achieved via amplification of the endogenous 'immune deviation' mechanism(s) that normally facilitate discrimination between pathogenic and non-pathogenic antigens at the mucosal surfaces of the body.
目前，过敏症领域的研究几乎完全集中在已确诊的过敏性疾病的治疗上。特别是，治疗主要集中在控制免疫炎症级联反应末端过敏效应细胞释放和作用各种介质，如细胞因子。在此，帕特里克·霍尔特认为，一个可能更有效且可实现的目标或许是在婴儿期预防初始T辅助2（Th2）细胞对环境过敏原的致敏。这或许可通过增强内源性“免疫偏离”机制来实现，该机制通常有助于在机体黏膜表面区分致病性和非致病性抗原。
